MCID: NTR003
MIFTS: 49

Natural Killer Cell Leukemia

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Natural Killer Cell Leukemia

MalaCards integrated aliases for Natural Killer Cell Leukemia:

Name: Natural Killer Cell Leukemia 12 15
Aggressive Nk-Cell Leukemia 12 60
Leukemia, Natural Killer Cell Large Granular Lymphocytic 74
Large Granular Lymphocyte Leukemia, Nk-Cell Type 12
Nk-Cell Large Granular Lymphocyte Leukemia 60
Aggressive Natural Killer Cell Leukemia 54
Aggressive Natural Killer-Cell Leukemia 74
Leukemia, Large Granular Lymphocytic 74
Aggressive Nk Cell Leukemia 54
Aggressive Nk-Cell Lymphoma 60
Abnormality of the Ankles 30
Nk-Cell Lgl Leukemia 60
Ankcl 60
Ankl 54

Characteristics:

Orphanet epidemiological data:

60
aggressive nk-cell leukemia
Inheritance: Multigenic/multifactorial,Not applicable; Age of onset: Adult; Age of death: adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:1035
NCIt 51 C8647
ICD10 34 C94.8
ICD10 via Orphanet 35 C94.7
UMLS via Orphanet 75 C1292777 C1522378
Orphanet 60 ORPHA86873

Summaries for Natural Killer Cell Leukemia

MalaCards based summary : Natural Killer Cell Leukemia, also known as aggressive nk-cell leukemia, is related to composite lymphoma and lichen sclerosus et atrophicus, and has symptoms including fever An important gene associated with Natural Killer Cell Leukemia is TIA1 (TIA1 Cytotoxic Granule Associated RNA Binding Protein), and among its related pathways/superpathways are NF-kappaB Signaling and JAK-STAT signaling pathway (KEGG). The drugs Ketamine and Levofloxacin have been mentioned in the context of this disorder. Affiliated tissues include nk cells, bone and t cells.

Related Diseases for Natural Killer Cell Leukemia

Diseases related to Natural Killer Cell Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 591)
# Related Disease Score Top Affiliating Genes
1 composite lymphoma 30.5 GZMB TIA1
2 lichen sclerosus et atrophicus 29.8 GZMB TIA1
3 panniculitis 29.7 GZMB NCAM1 TIA1
4 peripheral t-cell lymphoma 29.1 GZMB NCAM1 TIA1
5 lichen planus 29.0 GZMB IL4
6 tenosynovitis of foot and ankle 12.1
7 hemarthrosis 11.8
8 arthropathy 11.8
9 pigmented villonodular synovitis 11.4
10 tendinitis 11.3
11 hemophilia 11.3
12 tarsal tunnel syndrome 11.3
13 peroneal nerve paralysis 11.3
14 mesomelic dysplasia, kantaputra type 11.2
15 foot drop 11.2
16 tendinopathy 11.2
17 septic arthritis 11.2
18 osteonecrosis 11.2
19 exostosis 11.2
20 gout 11.2
21 fibular hemimelia 11.2
22 navicular bone, accessory 11.1
23 tendinosis 11.1
24 tenosynovial giant cell tumor 11.1
25 buschke-ollendorff syndrome 11.1
26 psoriatic arthritis 11.1
27 polymyositis 11.1
28 myopathy, distal, 1 11.1
29 polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 1 11.1
30 ulcer of lower limbs 11.1
31 behcet's syndrome arthropathy 11.1
32 distal myopathy with vocal cord weakness 11.0
33 arthrogryposis, distal, type 9 10.9
34 hand-foot-genital syndrome 10.9
35 larsen syndrome 10.9
36 bethlem myopathy 1 10.9
37 tarsal-carpal coalition syndrome 10.9
38 anemia, sideroblastic, and spinocerebellar ataxia 10.9
39 epiphyseal dysplasia, multiple, 2 10.9
40 epidermolysis bullosa simplex, autosomal recessive 2 10.9
41 poikiloderma, hereditary fibrosing, with tendon contractures, myopathy, and pulmonary fibrosis 10.9
42 spondyloepimetaphyseal dysplasia, di rocco type 10.9
43 ehlers-danlos syndrome, classic-like, 2 10.9
44 polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 2 10.9
45 emery-dreifuss muscular dystrophy 10.9
46 decubitus ulcer 10.9
47 childhood-onset nemaline myopathy 10.9
48 harding ataxia 10.9
49 welander distal myopathy, swedish type 10.9
50 leukemia 10.8

Graphical network of the top 20 diseases related to Natural Killer Cell Leukemia:



Diseases related to Natural Killer Cell Leukemia

Symptoms & Phenotypes for Natural Killer Cell Leukemia

UMLS symptoms related to Natural Killer Cell Leukemia:


fever

Drugs & Therapeutics for Natural Killer Cell Leukemia

Drugs for Natural Killer Cell Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 258)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
2
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
3
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
4
Ofloxacin Approved Phase 3 82419-36-1 4583
5
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 38904 498142
6
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
7
Iron Approved, Experimental Phase 3,Phase 1,Phase 2,Not Applicable 7439-89-6, 15438-31-0 27284 23925
8
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 209810-58-2, 11096-26-7
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
10
Dalteparin Approved Phase 3 9005-49-6
11
Heparin Approved, Investigational Phase 3,Not Applicable 9005-49-6 46507594 772
12
Ondansetron Approved Phase 3,Not Applicable 99614-02-5 4595
13
Caspofungin Approved Phase 3,Phase 2 162808-62-0, 179463-17-3 2826718 468682
14
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
15
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
16
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 93-14-1 3516
17
Dextromethorphan Approved Phase 3 125-71-3 5362449 5360696
18
Morphine Approved, Investigational Phase 3,Not Applicable 57-27-2 5288826
19
Etoposide Approved Phase 2, Phase 3,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
20
Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
21
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
22
Busulfan Approved, Investigational Phase 2, Phase 3,Early Phase 1 55-98-1 2478
23
Melphalan Approved Phase 2, Phase 3,Not Applicable 148-82-3 460612 4053
24
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
25 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
26 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Excitatory Amino Acids Phase 3
28 Anesthetics Phase 3
29 Anesthetics, Dissociative Phase 3
30 Neurotransmitter Agents Phase 3,Not Applicable
31 Excitatory Amino Acid Antagonists Phase 3
32 Analgesics Phase 3,Phase 2,Not Applicable
33 Anesthetics, Intravenous Phase 3
34 Anesthetics, General Phase 3
35 Central Nervous System Depressants Phase 3,Phase 1,Phase 2,Not Applicable
36 Anti-Infective Agents, Urinary Phase 3,Phase 1,Phase 2
37 Anti-Infective Agents Phase 3,Phase 1,Phase 2,Not Applicable
38 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 1,Phase 2,Not Applicable
39 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
41 Cytochrome P-450 CYP1A2 Inhibitors Phase 3,Not Applicable
42 Renal Agents Phase 3,Phase 1,Phase 2
43 Cola Phase 3,Phase 1,Phase 2
44 Immunologic Factors Phase 2, Phase 3,Phase 1,Not Applicable,Early Phase 1
45 Antirheumatic Agents Phase 2, Phase 3,Phase 1,Not Applicable,Early Phase 1
46 Antineoplastic Agents, Alkylating Phase 2, Phase 3,Phase 1,Early Phase 1,Not Applicable
47 Immunosuppressive Agents Phase 2, Phase 3,Phase 1,Not Applicable,Early Phase 1
48 Alkylating Agents Phase 2, Phase 3,Phase 1,Early Phase 1,Not Applicable
49 Narcotics Phase 3,Not Applicable
50 Analgesics, Opioid Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 128)
# Name Status NCT ID Phase Drugs
1 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
2 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
3 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
4 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
5 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
6 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
7 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
8 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
9 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
10 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
11 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
12 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
13 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
14 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
15 CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
16 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
17 Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies Completed NCT00481871 Phase 1, Phase 2 Pralatrexate Injection;Gemcitabine Hydrochloride
18 Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer Completed NCT00031980 Phase 2 cyclosporine
19 506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents Completed NCT00003635 Phase 2 nelarabine
20 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
21 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
22 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
23 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
24 Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Completed NCT00278213 Phase 2 cyclophosphamide;fludarabine phosphate;mitoxantrone hydrochloride
25 Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer Completed NCT00255749 Phase 2
26 Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer Completed NCT00237627 Phase 1, Phase 2 PS-341;Doxil;Velcade
27 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2 caspofungin acetate
28 Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer Completed NCT00003406 Phase 1, Phase 2 carboplatin;docetaxel;ifosfamide
29 Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer Completed NCT00002504 Phase 2
30 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00005804 Phase 2 cyclophosphamide
31 Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer Completed NCT00006225 Phase 1, Phase 2
32 TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies Recruiting NCT03849651 Phase 2 Cyclophosphamide;Thiotepa;Melphalan;Mesna;Blinatumomab
33 Prospective, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (Methotrexate, Cyclophosphamide) in Large Granular Lymphocytes Leukemia Recruiting NCT01976182 Phase 2 Methotrexate;Cyclophosphamide
34 A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL Recruiting NCT03239392 Phase 1, Phase 2 BNZ132-1-40
35 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Recruiting NCT01760655 Phase 2 Fludarabine phosphate;Thiotepa;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
36 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Recruiting NCT01384513 Phase 2 Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
37 Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies Recruiting NCT00002663 Phase 1, Phase 2
38 Alemtuzumab (Campath ) to Treat T-Large Granular Lymphocyte Leukemia Active, not recruiting NCT00345345 Phase 2
39 Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies Active, not recruiting NCT01643603 Phase 1, Phase 2 Dasatinib
40 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Active, not recruiting NCT01839916 Phase 2
41 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Active, not recruiting NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
42 Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Active, not recruiting NCT00104858 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
43 Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer Active, not recruiting NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
44 Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant Active, not recruiting NCT00078858 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
45 Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies Active, not recruiting NCT00040846 Phase 2 fludarabine phosphate;mycophenolate mofetil;cyclosporine
46 Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Active, not recruiting NCT01609816 Phase 1, Phase 2 Dasatinib
47 Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia Terminated NCT00363779 Phase 2 Cyclosporine
48 Methotrexate Followed by Fludarabine in Patients With T-Cell Large Granular Lymphocytic Leukemia Terminated NCT00278265 Phase 2 MTX followed by fludarabine
49 Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL) Terminated NCT01191749 Phase 2 Alemtuzumab
50 Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia Terminated NCT00360776 Phase 2 tipifarnib

Search NIH Clinical Center for Natural Killer Cell Leukemia

Genetic Tests for Natural Killer Cell Leukemia

Genetic tests related to Natural Killer Cell Leukemia:

# Genetic test Affiliating Genes
1 Abnormality of the Ankles 30

Anatomical Context for Natural Killer Cell Leukemia

MalaCards organs/tissues related to Natural Killer Cell Leukemia:

42
Nk Cells, Bone, T Cells, Bone Marrow, Kidney, Heart, Liver

Publications for Natural Killer Cell Leukemia

Articles related to Natural Killer Cell Leukemia:

(show top 50) (show all 100)
# Title Authors Year
1
Identification of a novel CCDC22 mutation in a patient with severe Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis and aggressive natural killer cell leukemia. ( 30706328 )
2019
2
Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia. ( 29148541 )
2018
3
Combination statin and chemotherapy inhibits proliferation and cytotoxicity of an aggressive natural killer cell leukemia. ( 30116531 )
2018
4
Successful Treatment of Pediatric Epstein-Barr Virus-positive Aggressive Natural Killer-Cell Leukemia. ( 29889803 )
2018
5
Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. ( 29674644 )
2018
6
Aggressive NK-Cell Leukemia. ( 30364049 )
2018
7
Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes. ( 29263371 )
2017
8
CD56-Negative Aggressive NK Cell Leukemia Relapsing as Multiple Cranial Nerve Palsies: Case Report and Literature Review. ( 29163992 )
2017
9
EBV-negative aggressive NK-cell leukemia/lymphoma: a clinical and pathological study from a single institution. ( 28548121 )
2017
10
Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis. ( 28161608 )
2017
11
Achievement of disease control with donor-derived EB virus-specific cytotoxic T cells after allogeneic peripheral blood stem cell transplantation for aggressive NK-cell leukemia. ( 27830541 )
2017
12
EBV-negative Aggressive NK-cell Leukemia/Lymphoma: Clinical, Pathologic, and Genetic Features. ( 27631517 )
2017
13
Aggressive natural killer cell leukemia: a case report. ( 29263706 )
2017
14
Aggressive natural killer cell leukemia or extranodal NK/T cell lymphoma? a case with nasal involvement. ( 28623913 )
2017
15
A relapsed aggressive NK-cell leukemia with CNS involvement diagnosed by cerebrospinal fluid examination. ( 26890009 )
2016
16
EBV-associated aggressive natural killer cell leukemia. ( 28092886 )
2016
17
A Pyrazolo[3,4-d]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemia. ( 27566560 )
2016
18
Flow Cytometric Immunophenotyping Is Sensitive for the Early Diagnosis of De Novo Aggressive Natural Killer Cell Leukemia (ANKL): A Multicenter Retrospective Analysis. ( 27483437 )
2016
19
Clinicopathologic Characterization of Aggressive Natural Killer Cell Leukemia Involving Different Tissue Sites. ( 26975038 )
2016
20
Aggressive natural killer cell leukemia associated with hemophagocytic lymphohistiocytosis. ( 28829754 )
2016
21
Aggressive natural killer cell leukemia associated with hemophagocytic lymphohistiocytosis ( 28829111 )
2016
22
L-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia. ( 27091029 )
2016
23
Aggressive NK-cell leukemia in a 69 years old Caucasian woman: a case report. ( 26682116 )
2015
24
Long complete remission achieved with the combination therapy of Cisplatin and gemcitabine in a patient with aggressive natural killer cell leukemia. ( 25694835 )
2015
25
18F-FDG PET for diagnosis and response assessment for aggressive NK cell leukemia. ( 23751830 )
2014
26
Spontaneous Hepatic Rupture Associated With Epstein-Barr Virus Negative Aggressive Natural Killer Cell Leukemia. ( 29147405 )
2014
27
Rare aggressive natural killer cell leukemia presented with bone marrow fibrosis - a diagnostic challenge. ( 25126488 )
2014
28
Aggressive natural killer-cell leukemia: classical presentation of a rare disease. ( 25118753 )
2014
29
Six cases of aggressive natural killer-cell leukemia in a Chinese population. ( 25031771 )
2014
30
Abnormal immunophenotype provides a key diagnostic marker: a report of 29 cases of de novo aggressive natural killer cell leukemia. ( 24524877 )
2014
31
Anti-cancer activity of gemcitabine against natural killer cell leukemia/lymphoma. ( 23772641 )
2014
32
A probable identical Epstein-Barr virus clone-positive composite lymphoma with aggressive natural killer-cell leukemia and cytotoxic T-cell lymphoma. ( 24427365 )
2014
33
Favorable outcome in a child with EBV-negative aggressive NK cell leukemia. ( 23550023 )
2013
34
Aggressive natural killer-cell leukemia with jaundice and spontaneous splenic rupture: a case report and review of the literature. ( 23510456 )
2013
35
Adult aggressive natural killer cell leukemia. ( 23241562 )
2013
36
Targeting glucosylceramide synthase synergizes with C6-ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia. ( 23181473 )
2013
37
Successful disease control with L-asparaginase monotherapy for aggressive natural killer cell leukemia with severe hepatic failure. ( 22891745 )
2013
38
Three cases of aggressive natural killer cell leukemia with a lethal hemorrhagic complication. ( 23037625 )
2012
39
Aggressive natural killer cell leukemia: therapeutic potential of L-asparaginase and allogeneic hematopoietic stem cell transplantation. ( 22360679 )
2012
40
Treatment of Aggressive NK-Cell Leukemia: A Case Report and Review of the Literature. ( 22937312 )
2011
41
F-18 FDG PET/CT findings of aggressive NK-cell leukemia. ( 21892052 )
2011
42
The diagnosis and management of extranodal NK/T-cell lymphoma, nasal-type and aggressive NK-cell leukemia. ( 21628857 )
2011
43
Ocular palsy associated with aggressive NK-cell leukemia. ( 21607654 )
2011
44
Collapsing glomerulopathy associated with natural killer cell leukemia: a case report and review of the literature. ( 21908087 )
2011
45
Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia. ( 21116747 )
2010
46
Long term survival in aggressive NK cell leukemia. ( 21048272 )
2010
47
Successful allogeneic hematopoietic stem cell transplantation for aggressive NK cell leukemia. ( 20823655 )
2010
48
Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. ( 19850638 )
2010
49
Sustained CR of refractory aggressive natural killer cell leukemia following unrelated cord blood transplantation. ( 20676148 )
2010
50
Frequent CD7 antigen loss in aggressive natural killer-cell leukemia: a useful diagnostic marker. ( 20046078 )
2009

Variations for Natural Killer Cell Leukemia

Expression for Natural Killer Cell Leukemia

Search GEO for disease gene expression data for Natural Killer Cell Leukemia.

Pathways for Natural Killer Cell Leukemia

GO Terms for Natural Killer Cell Leukemia

Cellular components related to Natural Killer Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.1 B3GAT1 EPO IL4 IL7 MPO NCAM1

Biological processes related to Natural Killer Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.46 CD2 EPO GZMB TIA1
2 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.37 EPO IL4
3 T cell activation GO:0042110 9.32 CD2 IL4
4 positive regulation of B cell proliferation GO:0030890 9.26 IL4 IL7
5 negative regulation of apoptotic process GO:0043066 9.26 EPO IL4 IL7 MPO
6 positive regulation of T cell differentiation GO:0045582 8.62 IL4 IL7

Molecular functions related to Natural Killer Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.13 EPO IL4 IL7
2 cytokine receptor binding GO:0005126 8.62 IL4 IL7

Sources for Natural Killer Cell Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....